<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4724">
  <stage>Registered</stage>
  <submitdate>27/11/2014</submitdate>
  <approvaldate>27/11/2014</approvaldate>
  <nctid>NCT02305420</nctid>
  <trial_identification>
    <studytitle>EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage</studytitle>
    <scientifictitle>EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage</scientifictitle>
    <utrn />
    <trialacronym>BlastGen</trialacronym>
    <secondaryid>8114</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Recurrent Miscarriage</healthcondition>
    <healthcondition>Infertility</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fetal medicine and complications of pregnancy</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Abortion</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - EmbryoGen/ BlastGen media
Treatment: devices - Standard Cook sequential media

Experimental: EmbryoGen/BlastGen - EmbryoGen and BlasGen media containing GM-CSF 2ng/ml will be used in the experimental arm

Active Comparator: Control - Standard Cook sequential media


Treatment: devices: EmbryoGen/ BlastGen media
Embryos will be cultured in media containing Gm-CSF (EmbryoGen/BlastGen)

Treatment: devices: Standard Cook sequential media
Standard Cook IVF media will be used in the control arm

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Livebirth &gt;20 weeks - Any delivery &gt;20 resulting in a livebirth</outcome>
      <timepoint>9 months after closure of trial (18 +9 months)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Congenital Anomaly Rate - number of liveborns with a congenital anomaly</outcome>
      <timepoint>9 months after closure of trial (18 +9 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical pregnancy rates at 7 and 12 weeks gestation - Fetal Heart Beat seen on Ultrasound scan at 7 and 12 weeks</outcome>
      <timepoint>18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of embryos reaching blastocyst stage - Number of blastocysts per cycle</outcome>
      <timepoint>18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Day 3 and day 5 embryo scores - grade of day 3 and day 5 embryos</outcome>
      <timepoint>18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cryopreservation outcomes - Number of Frozen blastocysts</outcome>
      <timepoint>18 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  women undertaking an IVF or ICSI cycle

               -  aged between 25 and 41 years

               -  2 or more embryos transferred without a positive pregnancy outcome OR a history
                  of at least 1 previous pregnancy loss, OR

               -  Poor embryo development (&lt;20% of embryo developing on time at Day 3 or no
                  blastocyst above Grade 2 on Day 5)</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>41</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  male partner requiring surgical retrieval of sperm except in cases of previous
             vasectomy

          -  the use of another investigational drug within 30 days

          -  any severe chronic disease that would significantly influence an IVF cycle

          -  less than 3 follicles&gt;14mm on ultrasound on the day of HCG trigger</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>FertilitySA - Adelaide</hospital>
    <postcode>5006 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>FertilitySA</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Adelaide</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>EmbryoGen and BlastGen contain the cytokine growth factor Granulocyte-Macrophage
      Colony-Stimulating Factor (GM-CSF), which has been documented to give significant benefit to
      this difficult group of patients.

      Results showed a highly significant effect of 44% relative improvement in ongoing
      implantation rate (p=0.001) in women who have previously miscarried (Ziebe et al 2013).

      We wish to undertake a randomised Controlled trial to determine if EmbryoGen/BlastGen media
      improves pregnancy outcomes in women with recurrent implantation failure, recurrent
      miscarriage and poor embryo development when compared to standard media.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02305420</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Mary L Hull, PhD, FRANZCOG</name>
      <address />
      <phone>+61 8 8100 2900</phone>
      <fax />
      <email>louise.hull@adelaide.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>